Progress in the search for circulating biomarkers of nonalcoholic fatty liver disease

Biomarkers

Volumn 19, Issue 7, 2014, Pages 541-552

  Amacher, David E ^a  

^a Sciadvisor Toxicology Consulting   (United States)

Author keywords

Non alcoholic fatty liver disease; Non alcoholic steatosis; Novel circulating biomarkers; Steatohepatitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; BILIRUBIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGEN TYPE 3; CYTOKERATIN 18; FIBROBLAST GROWTH FACTOR 21; GAMMA GLUTAMYLTRANSFERASE; HAPTOGLOBIN; HYALURONIC ACID; MICRORNA; MICRORNA 122; MICRORNA 155; MICRORNA 16; MICRORNA 21; MICRORNA 34A; MICRORNA 451; PENTRAXIN; PROLINE DIPEPTIDASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; UNCLASSIFIED DRUG;

DISEASE COURSE; FATTY LIVER; HUMAN; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PROTEIN BLOOD LEVEL; REVIEW; BLOOD; GENETICS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; LIVER; MICRORNAS; NON-ALCOHOLIC FATTY LIVER DISEASE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 84912049396     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2014.958535     Document Type: Review

References (113)

1. Adam L, Wszolek MF, Liu CG, et al. (2013). Plasma microRNA profiles for bladder cancer detection. Urol Oncol 31:1701-8.
2. Adams LA, Angulo P, Lindor KD. (2005). Nonalcoholic fatty liver disease. CMAJ 172:899-905.
3. Amacher DE, Chalasani N. (2014). Drug-induced steatosis. Semin Liver Dis 34:205-14.
4. Anglicheau D, Muthukumar T, Suthanthiran M. (2010). MicroRNAs: small RNAs with big effects. Transplantation 90:105-12.
5. Angulo P, Hui JM, Marchesini G, et al. (2007). The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology 45:846-54.
6. Angulo P. (2007). GI epidemiology: nonalcoholic fatty liver disease. Aliment Pharmacol Ther 25:883-9.
7. Antoine DJ, Jenkins RE, Dear JW, et al. (2012). Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol 56:1070-9.
8. Arroyo JD, Chevillet JR, Kroh EM, et al. (2011). Argonaute2 complexes carry a population of circulating micrornas independent of vesicles in human plasma. Proc Natl Acad Sci USA 108:5003-8.
9. Barsić N, Lerotić I, Smircić-Duvnjak L, et al. (2012). Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 18, 3945-54.
10. Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. (2013). Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 19:1166-72.
11. Bellentani S, Saccoccio G, Masutti F, et al. (2000). Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112-17.
12. Benet M, Moya M, Donato MT, et al. (2014). A simple transcriptomic signature able to predict drug-induced hepatic steatosis. Arch Toxicol 88:967-82.
13. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. (2014). Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 7:221-39.
14. Bozkurt M, Caglayan M, Oktayoglu P, et al. (2014). Serum prolidase enzyme activity and oxidative status in patients with fibromyalgia. Redox Rep 19:148-53.
15. Bravo AA, Sheth SG, Chopra S. (2001). Liver biopsy. N Engl J Med 344: 495-500.
16. Browning JD, Szczepaniak LS, Dobbins R, et al. (2004). Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 40:1387-95.
17. Brunt EM, Kleiner DE, Wilson LA, et al; NASH Clinical Research Network (CRN).(2011). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 53:810-20.
18. Cao W, Zhao C, Shen C, Wang Y. (2013). Cytokeratin 18, alanine aminotransferase, platelets and triglycerides predict the presence of nonalcoholic steatohepatitis. PLoS One 8:e82092.
19. Castéra L, Foucher J, Bernard PH, et al. (2010). Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 51:828-35.
20. Castro RE, Ferreira DM, Afonso MB, et al. (2013). miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol 58:119-25.
21. Cauĺn C, Salvesen GS, Oshima RG. (1997) Caspase cleavage of keratin 18 and reorganization of intermediate filaments during epithelial cell apoptosis. J Cell Biol 138, 1379-94
22. Ceccarelli S, Panera N, Gnani D, Nobili V. (2013). Dual Role of MicroRNAs in NAFLD. Int J Mol Sci 14:8437-55.
23. Cermelli S, Ruggieri A, Marrero JA, et al. (2011). Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 6:e23937.
24. Chalasani N, Younossi Z, Lavine JE, et al. (2012). The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 55:2005-23.
25. Chen J, Zhu Y, Zheng Q, Jiang J. (2013). Serum cytokeratin-18 in the diagnosis of non-alcoholic steatohepatitis: a meta-analysis. Hepatol Res 44:854-62.
26. Cheung O, Puri P, Eicken C, et al. (2008). Nonalcoholic steatohepatitis is associated with altered hepatic MicroRNA expression. Hepatology 48: 1810-20.
27. Craig DG, Lee P, Pryde EA, et al. (2011). Circulating apoptotic and necrotic cell death markers in patients with acute liver injury. Liver Int 31:1127-36.
28. Cusi K, Chang Z, Harrison S, et al. (2014). Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol 60: 167-74.
29. Donnelly KL, Smith CI, Schwarzenberg SJ, et al. (2005). Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343-51.
30. Dushay J, Chui PC, Gopalakrishnan GS, et al. (2010). Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 139:456-63.
31. Esau C, Davis S, Murray SF, et al. (2006). miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 3: 87-98.
32. Estep M, Armistead D, Hossain N, et al. (2010). Differential expression of miRNAs in the visceral adipose tissue of patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 32:487-97.
33. Feldstein AE, Alkhouri N, De Vito R, et al. (2013). Serum cytokeratin-18 fragment levels are useful biomarkers for nonalcoholic steatohepatitis in children. Am J Gastroenterol 108:1526-31.
34. Feldstein AE, Canbay A, Angulo P, et al. (2003). Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology 125:437-43.
35. Fernández-Hernando C, Suárez Y, Rayner KJ, Moore KJ. (2011). MicroRNAs in lipid metabolism. Curr Opin Lipidol 22:86-92.
36. Fernández-Hernando C. (2013). Emerging role of microRNAs in the regulation of lipid metabolism. Hepatology 57:432-4.
37. Friedman SL. (2000). Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247-50.
38. Fu T, Choi SE, Kim DH, et al. (2012). Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor b-Klotho. Proc Natl Acad Sci USA 109: 16137-42.
39. Gälman C, Lunda°sen T, Kharitonenkov A, et al. (2008). The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 8:169-74.
40. Gariani K, Drifte G, Dunn-Siegrist I, et al. (2013). Increased FGF21 plasma levels in humans with sepsis and SIRS. Endocr Connect 2: 146-53.
41. Gecit I, Aslan M, Gunes M, et al. (2012). Serum prolidase activity, oxidative stress, and nitric oxide levels in patients with bladder cancer. J Cancer Res Clin Oncol 138:739-43.
42. Goodsaid FM, Frueh FW, Mattes W. (2007). The Predictive Safety Testing Consortium: a synthesis of the goals, challenges and accomplishments of the critical path. Drug Discov Today Technol Winter 4:47-50.
43. Guha IN, Parkes J, Roderick P, et al. (2008). Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology 47: 455-60.
44. Hashemi M, Hanafi Bojd H, Eskandari Nasab E, et al. (2013). Association of adiponectin rs1501299 and rs266729 gene polymorphisms with nonalcoholic fatty liver disease. Hepat Mon 13:e9527. doi: 10.5812/hepatmon.9527.
45. Horoz M, Aslan M, Bolukbas FF, et al. (2010). Serum prolidase enzyme activity and its relation to histopathological findings in patients with non-alcoholic steatohepatitis. J Clin Lab Anal 24:207-11.
46. Hoyumpa Jr AM, Greene HL, Dunn GD, Schenker S. (1975). Fatty liver: biochemical and clinical considerations. Am J Dig Dis 20: 1142-70.
47. Iglesias P, Selgas R, Romero S, Déz JJ. (2012). Biological role, clinical significance, and therapeutic possibilities of the recently discovered metabolic hormone fibroblastic growth factor 21. Eur J Endocrinol 167:301-9.
48. Jin X, Ye YF, Chen SH, et al. (2009). MicroRNA expression pattern in different stages of nonalcoholic fatty liver disease. Dig Liver Dis 41: 289-97.
49. Kaiser JP, Lipscomb JC, Wesselkamper SC. (2012). Putative mechanisms of environmental chemical-induced steatosis. Int J Toxicol 31: 551-63.
50. Kawano Y, Cohen DE. (2013). Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease. J Gastroenterol 48: 434-41.
51. Kayadibi H, Gültepe M, Yasar B, et al. (2009). Diagnostic value of serum prolidase enzyme activity to predict the liver histological lesions in non-alcoholic fatty liver disease: a surrogate marker to distinguish steatohepatitis from simple steatosis. Dig Dis Sci 54: 1764-71.
52. Kleiner DE, Brunt EM, Van Natta M, et al; Nonalcoholic Steatohepatitis Clinical Research Network. (2005). Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41:1313-21.
53. Kogiso T, Moriyoshi Y, Shimizu S, et al. (2009). High-sensitivity C-reactive protein as a serum predictor of nonalcoholic fatty liver disease based on the Akaike information criterion scoring system in the general Japanese population. J Gastroenterol 44:313-21.
54. Koo SH. (2013). Non-alcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 19:210-15.
55. Lakner AM, Bonkovsky HL, Schrum LW. (2011). MicroRNAs: fad or future of liver disease. World J Gastroenterol 17:2536-42.
56. Lewis SPJ, Dear J, Platt V, et al. (2011). Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 54: 1767-76.
57. Li H, Fang Q, Gao F, et al. (2010). Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 53:934-40.
58. Li WQ, Chen C, Xu MD, et al. (2011). The rno-miR-34 family is upregulated and targets ACSL1 in dimethylnitrosamine-induced hepatic fibrosis in rats. FEBS J 278:1522-32.
59. Li Y, Kowdley KV. (2012). MicroRNAs in common human diseases. Genomics Proteomics Bioinformatics 10:246-53.
60. Li YY. (2012). Genetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease. World J Gastroenterol 18:6546-51.
61. Ludwig J, Viggiano TR, McGill DB, Oh BJ. (1980). Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55:434-8.
62. Malik R, Chang M, Bhaskar K, et al. (2009). The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 24:564-8.
63. Martn-Rodŕguez JL, Arrebola JP, Jiménez-Moleón JJ, et al. (2014). Sonographic quantification of a Hepato-Renal Index for the assessment of hepatic steatosis in comparison with 3T proton magnetic resonance spectroscopy. Eur J Gastroenterol Hepatol 26. 88-94.
64. Masuoka HC, Chalasani N. (2013). Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci 1281:106-22.
65. Meng F, Glaser SS, Francis H, et al. (2012). Epigenetic regulation of miR-34a expression in alcoholic liver injury. Am J Pathol 181:804-17.
66. Merz M. (2014). The European IMI SAFE-T Consortium: progress and challenges. FDA/C-Path DILI Conference XIV, 2014 March 19-20; Hyattsville, MD. Available from: http://www.aasld.org/dili/Documents/2014/IIIB-2-Merz-mm.pdf [last accessed 16 Aug 2014].
67. Min HK, Kapoor A, Fuchs M, et al. (2012). Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 15:665-74.
68. Mitchell PS, Parkin RK, Kroh EM, et al. (2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105:10513-18.
69. Miyaaki H, Ichikawa T, Kamo Y, et al. (2013). Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int 37:e302-7.
70. Moylan CA, Pang H, Dellinger A, et al. (2014). Hepatic gene expression profiles differentiate pre-symptomatic patients with mild versus severe nonalcoholic fatty liver disease. Hepatology 59:471-82.
71. Neuschwander-Tetri BA, Caldwell SH. (2003). Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 37:1202-19.
72. Obika M, Noguchi H. (2012). Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res 2012:Article ID: 103063. doi: 10.1155/2012/145754.
73. Palka JA, Phang JM. (1997). Prolidase activity in fibroblasts is regulated by interaction of extracellular matrix with cell surface integrin receptors. J Cell Biochem 67:166-75.
74. Palmeri ML, Wang MH, Rouze NC, et al. (2011). Noninvasive evaluation of hepatic fibrosis using acoustic radiation force-based shear stiffness in patients with nonalcoholic fatty liver disease. J Hepatol 55:666-72.
75. Puri P, Baillie RA, Wiest MM, et al. (2007). A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 46:1081-90.
76. Puri P, Wiest MM, Cheung O, et al. (2009). The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology 50:1827-38.
77. Qayyum A, Chen DM, Breiman RS, et al. (2009). Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best Clin Imaging 33:110-15
78. Ratziu V, Massard J, Charlotte F, et al; LIDO Study Group; CYTOL study group. (2006). Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol 6:6.
79. Reinehr T, Woelfle J, Wunsch R, Roth CL. (2012). Fibroblast growth factor 21 (FGF-21) and its relation to obesity, metabolic syndrome, and nonalcoholic fatty liver in children: a longitudinal analysis. J Clin Endocrinol Metab 97:2143-50.
80. Sacco J, Adeli K. (2012). MicroRNAs: emerging roles in lipid and lipoprotein metabolism. Curr Opin Lipidol 23:220-5.
81. Sakugawa H, Nakayoshi T, Kobashigawa K, et al. (2004). Alanine aminotransferase elevation not associated with fatty liver is frequently seen in obese Japanese women. Eur J Clin Nutr 58:1248-52.
82. Sakugawa H, Nakayoshi T, Kobashigawa K, et al. (2005). Clinical usefulness of biochemical markers of liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 11:255-9.
83. Schamberger A, Sarkadi B, Orban TI. (2012). Human mirtrons can express functional microRNAs simultaneously from both arms in a flanking exon-independent manner. RNA Biol 9:1177-85.
84. Schultz A, Neil D, Aguila MB, Mandarim-de-Lacerda CA. (2013). Hepatic adverse effects of fructose consumption independent of overweight/obesity. Int J Mol Sci 14:21873-86.
85. Shen J, Chan HL, Wong GL, et al. (2012). Non-invasive diagnosis of non-alcoholic steatohepatitis by combined serum biomarkers. J Hepatol 56:1363-70.
86. Shifeng H, Danni W, Pu C, et al. (2013). Circulating liver-specific miR-122 as a novel potential biomarker for diagnosis of cholestatic liver injury. PLoS One:e73133.
87. Simental-Mendá LE, Rodŕguez-Hernández H, Rodŕguez-Morán M, Guerrero-Romero F. (2012). The alanine aminotransferase to triglycerides ratio as a marker to identify nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 24, 1173-7.
88. Soga T, Sugimoto M, Honma M, et al. (2011). Serum metabolomics reveals g-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol 55:896-905.
89. Tabuchi M, Tomioka K, Kawakami T, et al. (2010). Serum cytokeratin 18 M30 antigen level and its correlation with nutritional parameters in middle-aged Japanese males with nonalcoholic fatty liver disease (NAFLD). J Nutr Sci Vitaminol (Tokyo) 56:271-8.
90. Tomizawa M, Kawanabe Y, Shinozaki F, et al. (2014). Elevated levels of alanine transaminase and triglycerides within normal limits are associated with fatty liver. Exp Ther Med 8:759-62.
91. Trebicka J, Anadol E, Elfimova N, et al. (2013). Hepatic and serum levels of miR-122 after chronic HCV-induced fibrosis. J Hepatol 58: 234-9.
92. Tryndyak VP, Latendresse JR, Montgomery B, et al. (2012). Plasma microRNAs are sensitive indicators of inter-strain differences in the severity of liver injury induced in mice by a choline-and folatedeficient diet. Toxicol Appl Pharmacol 262:52-9.
93. Tsutsui M, Tanaka N, Kawakubo M, et al. (2010). Serum fragmented cytokeratin 18 levels reflect the histologic activity score of nonalcoholic fatty liver disease more accurately than serum alanine aminotransferase levels. J Clin Gastroenterol 44:440-7.
94. Ueno T, Toi M, Linder S. (2005). Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 59: S359-62.
95. Vuppalanchi R, Jain AK, Deppe R, et al. (2014). Relationship between changes in serum levels of keratin 18 and changes in liver histology in children and adults with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol (In press). doi: http://dx.doi.org/10.1016/j.cgh.2014.05.010.
96. Wang K, Zhang S, Marzolf B, et al. (2009). Circulating microRNAs, potential biomarkers for drug-induced liver injury. Proc Natl Acad Sci USA 106:4402-7.
97. Whittaker R, Loy PA, Sisman E, et al. (2010). Identification of MicroRNAs that control lipid droplet formation and growth in hepatocytes via high-content screening. J Biomol Screen 15:798-805.
98. Wieckowska A, McCullough AJ, Feldstein AE. (2007). Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology 46:582-9.
99. Woodcock J, Woosley R. (2008). The FDA critical path initiative and its influence on new drug development. Annu Rev Med 59:1-12.
100. Xu J, Lloyd DJ, Hale C, et al. (2009). Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250-9.
101. Xu J, Wu C, Che X, et al. (2011). Circulating microRNAs, miR-21, miR-122, and miR-223, in patients with hepatocellular carcinoma or chronic hepatitis. Mol Carcinog 50:136-42.
102. Yamada H, Suzuki K, Ichino N, et al. (2013). Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 424:99-103.
103. Yamaura Y, Nakajima M, Takagi S, et al. (2012). Plasma microRNA profiles in rat models of hepatocellular injury, cholestasis, and steatosis. PLoS One 7:e30250.
104. Yan H, Xia M, Chang X, et al. (2011). Circulating fibroblast growth factor 21 levels are closely associated with hepatic fat content: a crosssectional study. PLoS One 6:e24895.
105. Yilmaz Y, Dolar E, Ulukaya E, et al. (2007). Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. World J Gastroenterol 13:837-44.
106. Yilmaz Y, Eren F, Yonal O, et al. (2010). Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease. Eur J Clin Invest 40: 887-92.
107. Yoneda M, Mawatari H, Fujita K, et al. (2007). High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 42:573-82.
108. Younossi ZM, Jarrar M, Nugent C, et al. (2008). A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 18:1430-7.
109. Zelber-Sagi S, Salomone F, Yeshua H, et al. (2014). Non-high-density lipoprotein cholesterol independently predicts new onset of nonalcoholic fatty liver disease. Liver Int 34:e128-35.
110. Zelber-Sagi S, Webb M, Assy N, et al. (2013). Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. World J Gastroenterol 19:57-64.
111. Zhang X, Yeung DC, Karpisek M, et al. (2008). Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57:1246-53.
112. Zhang Y, Jia Y, Zheng R, et al. (2010). Plasma microRNA-122 as a biomarker for viral-, alcohol-, and chemical-related hepatic diseases. Clin Chem 56:1830-8.
113. Zhong D, Huang G, Zhang Y, et al. (2013). MicroRNA-1 and microRNA-206 suppress LXRa-induced lipogenesis in hepatocytes. Cell Signal 25:1429-37.